These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 33919025)

  • 1. Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease.
    Acharya S; Kim KM
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.
    De Deurwaerdère P; Di Giovanni G; Millan MJ
    Prog Neurobiol; 2017 Apr; 151():57-100. PubMed ID: 27389773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt/β-catenin signaling plays an essential role in α7 nicotinic receptor-mediated neuroprotection of dopaminergic neurons in a mouse Parkinson's disease model.
    Liu Y; Hao S; Yang B; Fan Y; Qin X; Chen Y; Hu J
    Biochem Pharmacol; 2017 Sep; 140():115-123. PubMed ID: 28551099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
    Ztaou S; Maurice N; Camon J; Guiraudie-Capraz G; Kerkerian-Le Goff L; Beurrier C; Liberge M; Amalric M
    J Neurosci; 2016 Aug; 36(35):9161-72. PubMed ID: 27581457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia.
    Conti MM; Chambers N; Bishop C
    Neurosci Biobehav Rev; 2018 Sep; 92():67-82. PubMed ID: 29782883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
    Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The striatal cholinergic system in L-dopa-induced dyskinesias.
    Perez XA; Bordia T; Quik M
    J Neural Transm (Vienna); 2018 Aug; 125(8):1251-1262. PubMed ID: 29492663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemogenetic modulation of cholinergic interneurons reveals their regulating role on the direct and indirect output pathways from the striatum.
    Aldrin-Kirk P; Heuer A; Rylander Ottosson D; Davidsson M; Mattsson B; Björklund T
    Neurobiol Dis; 2018 Jan; 109(Pt A):148-162. PubMed ID: 29037828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the cholinergic system in Parkinson's disease.
    Liu C
    Acta Pharmacol Sin; 2020 Apr; 41(4):453-463. PubMed ID: 32132659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
    Jellinger KA
    J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
    Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
    J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.
    Quik M; Wonnacott S
    Pharmacol Rev; 2011 Dec; 63(4):938-66. PubMed ID: 21969327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Pharmacotherapies in Parkinson's Disease.
    Tizabi Y; Getachew B; Aschner M
    Neurotox Res; 2021 Aug; 39(4):1381-1390. PubMed ID: 34003454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinergic aspects of schizophrenia.
    Tandon R
    Br J Psychiatry Suppl; 1999; (37):7-11. PubMed ID: 10211133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?
    Bisaglia M; Filograna R; Beltramini M; Bubacco L
    Ageing Res Rev; 2014 Jan; 13():107-14. PubMed ID: 24389159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease.
    Ztaou S; Amalric M
    Neurochem Int; 2019 Jun; 126():1-10. PubMed ID: 30825602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopmine-Induced Rat Model of Parkinson's Disease is Mediated by α7-Nicotinic Receptors.
    El Nebrisi E; Javed H; Ojha SK; Oz M; Shehab S
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
    PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.